ArticlePoultry science2026
Development and evaluation of bovine adenovirus vector-based avian influenza vaccine efficacy in poultry.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Avian influenza virus (AIV) remains a persistent threat to global poultry health and production, necessitating the development of novel and effective vaccination strategies. This study evaluated the immunogenicity and protective efficacy of a newly developed bovine adenovirus-vector-based avian influenza virus (BAdV-AIV) vaccine expressing the hemagglutinin (HA) gene of H5N1 and the nucleoprotein (NP) gene of H7N9 AIV subtypes (BAdV - (H5N1)HA+(H7N9)NP). In our study, the candidate vaccine was administered via three mucosal routes: oral (OR), intranasal (IN), or intraocular (IO), using three different doses (10⁶, 10⁷, and 10⁸ pfu/bird) in a prime-boost vaccination regimen in broiler chickens. Immunological analyses revealed that high-dose vaccination, administered via the IO route induced a substantial upregulation of virus-specific systemic IgY, hemagglutination inhibition (HI) antibody titers, mucosal sIgA antibody responses in bile, trachea and intestines, and activation of various T-cell subsets (helper T cells, cytotoxic T cells, and γδ T lymphocytes). The quantitative PCR (qPCR) assay failed to detect a difference in the challenge H5N2 AIV genomic equivalent load in the vaccinated groups. A qualitative analysis for live challenge virus detection was performed by inoculating the tracheal swab fluid into embryonated chicken eggs and harvested allantoic fluid was tested by hemagglutination assay. Our data showed a lower percentage of tracheal samples yielding detectable live virus in the high-dose BAdV-(H5N1)HA+H7N9)NP AIV vaccine group, particularly following IO administration, compared with the other vaccination routes. Overall, the BAdV-(H5N1)HA+ (H7N9)NP vaccine elicited AIV-specific humoral, mucosal, and cellular immune responses and was associated with a reduced percentage of virus-isolation-positive tracheal samples, particularly following IO administration. These findings support the need for further evaluation of this vaccine platform for avian influenza control in poultry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.